A Phase 2, Multicentre, Double-Blind, Placebo-Controlled, Dose Escalating Trial of the Safety, Pharmacokinetics, and Biological Activity of 3 Consecutive Daily Doses of Serp-1 When Added to Conventional Therapy in Patients With Acute Coronary Syndromes (Non ST-Elevation Myocardial Infarction and/or Unstable Angina)

Trial Profile

A Phase 2, Multicentre, Double-Blind, Placebo-Controlled, Dose Escalating Trial of the Safety, Pharmacokinetics, and Biological Activity of 3 Consecutive Daily Doses of Serp-1 When Added to Conventional Therapy in Patients With Acute Coronary Syndromes (Non ST-Elevation Myocardial Infarction and/or Unstable Angina)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Dec 2010

At a glance

  • Drugs VT 111 (Primary)
  • Indications Acute coronary syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Dec 2010 Results were published in Circulation: Cardiovascular Interventions, according to a Viron Therapeutics media release.
    • 18 Nov 2009 Secondary endpoint 'Creatine kinase MB isoenzyme level' has been met.
    • 18 Nov 2009 Secondary endpoint 'Troponin level' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top